Phase 2 Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 to 65 years old
- People who are willing and able to sign a consent form agreeing to take part
- People who have been diagnosed with major depressive disorder (MDD)
- People whose depression has not improved enough after trying at least two different antidepressant medications, with at least one of those unsuccessful attempts happening during their current episode of depression
- People who are currently taking an approved antidepressant at a steady, unchanged dose before the screening appointment
- People whose depression is rated as severe enough at both the screening and baseline appointments, based on three specific assessment tools used by the study team
- Women who could become pregnant must have a negative pregnancy test and agree to use an accepted form of contraception during the trial; men must agree to use barrier contraception and not donate sperm during the trial
Who may not be able to join:
- People who have a current diagnosis of certain personality disorders or long-term (persistent) depressive disorder
- People with a recent history of substance use disorders, not including caffeine or nicotine
- People who are currently considered to be at active risk of suicide, or who have recently attempted suicide
- People with a history of schizophrenia, psychotic disorders, bipolar disorder, or depression with psychotic features
- People who are currently receiving treatment for PTSD, acute stress disorder, panic disorder, or OCD
- People with a history of two rare but serious medication reactions (neuroleptic malignant syndrome or serotonin syndrome), or a history of epilepsy (except for a single febrile seizure in infancy)
- People whose depression has previously not responded to ketamine or esketamine treatment
- People with a known allergy or sensitivity to ketamine or esketamine
- People with significant heart or cardiovascular disease
- People with a known history of hepatitis B, hepatitis C, or HIV infection
- People with unstable diabetes or other poorly controlled medical conditions
- People who test positive for illicit drugs or cannabis in a urine test
- People who have received brain stimulation treatments — such as ECT, TMS, VNS, or DBS — during their current depressive episode
- People who have recently started or made changes to their psychotherapy
Additional criteria not listed here may also apply, and the trial team will assess eligibility at the screening appointment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +1(609) 250-6920
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 28
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.